Enhancer of zeste homolog 2 inhibitors

US9505745B2 · kind B2 · utility

Assignee

• GlaxoSmithKline Intellectual Property (No. 4) Limited · GB

Inventors

• Charles William Blackledge, Jr. · Spring City, US
• Joelle Lorraine Burgess · Collegeville, US
• Neil W. Johnson · Collegeville, US
• Jiri Kasparec · King of Prussia, US
• Steven David Knight · West Chester, US
• Louis Lafrance · Collegeville, US
• Juan Luengo · Collegeville, US
• William Henry Miller · Collegeville, US
• Kenneth A. Newlander · West Chester, US
• Stuart Paul Romeril · Collegeville, US
• Mark Schulz · Skippack, US
• Dai-Shi Su · New York, US
• Xinrong Tian · Collegeville, US

Key dates

• Filing date: Apr 25, 2014
• Grant date: Nov 29, 2016
• Expiry date: Apr 25, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.